Abbott Laboratories (MEX:ABT) Short-Term Debt: MXN79,506 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:ABT Abbott Laboratories MEX:ABT
77 GF Score
Price MXN1,543.00
GF Value MXN2,254.78
Valuation Significantly Undervalued
! 1 Warning Sign
View Full Analysis

What is Abbott Laboratories Short-Term Debt?

Abbott Laboratories MEX:ABT -0.45% 77 Short-Term Debt is MXN79,506 Mil as of Mar. 2026. GuruFocus rates MEX:ABT with a GF Score™ of 77/100 and a GF Value™ of MXN2,254.78 (Significantly Undervalued). The stock has 1 warning sign investors should review.

Abbott Laboratories's Short-Term Debt for the quarter that ended in Mar. 2026 was MXN79,506 Mil.

Abbott Laboratories's quarterly Short-Term Debt increased from Sep. 2025 (MXN24,673 Mil) to Dec. 2025 (MXN54,611 Mil) and increased from Dec. 2025 (MXN54,611 Mil) to Mar. 2026 (MXN79,506 Mil).

Abbott Laboratories's annual Short-Term Debt increased from Dec. 2023 (MXN18,332 Mil) to Dec. 2024 (MXN31,284 Mil) and increased from Dec. 2024 (MXN31,284 Mil) to Dec. 2025 (MXN54,611 Mil).

Abbott Laboratories Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Abbott Laboratories Short-Term Debt Related Terms

Abbott Laboratories Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Abbott Laboratories's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Abbott Laboratories Short-Term Debt Chart

Abbott Laboratories Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 15,467.56 43,885.50 18,332.19 31,283.55 54,611.29

Abbott Laboratories Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10,351.85 9,546.40 24,672.95 54,611.29 79,506.17
MEX:ABT
77GF Score
Abbott Laboratories MEX:ABT
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of MXN79,506 Mil mean?
Abbott Laboratories (MEX:ABT) has a Short-Term Debt of MXN79,506 Mil as of Mar. 2026.
Is Abbott Laboratories' Short-Term Debt too high?
Abbott Laboratories' current Short-Term Debt is MXN79,506 Mil. Overall, Abbott Laboratories has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Abbott Laboratories' Short-Term Debt compare to SYK and MDT?
Abbott Laboratories' Short-Term Debt of MXN79,506 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Medical Devices & Instruments company?
A good Short-Term Debt depends on the Medical Devices & Instruments industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Abbott Laboratories's current Short-Term Debt is MXN79,506 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abbott Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Abbott Laboratories (MEX:ABT) is currently considered Significantly Undervalued. The stock's GF Value™ is MXN2,254.78, compared to a current price of MXN1,543.00 — trading 31.6% below its estimated fair value. The current Short-Term Debt is MXN79,506 Mil. Abbott Laboratories' overall GF Score™ is 77/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Abbott Laboratories (MEX:ABT), the current Short-Term Debt is MXN79,506 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Abbott Laboratories (MEX:ABT) Overvalued in 2026?

Based on GuruFocus' analysis, Abbott Laboratories stock appears to be undervalued. The current stock price of MXN1,543.00 is trading 31.6% below its estimated GF Value™ of MXN2,254.78. GuruFocus considers Abbott Laboratories to be Significantly Undervalued.

Key valuation signals for MEX:ABT:

  • Short-Term Debt: MXN79,506 Mil
  • GF Value™: MXN2,254.78 vs. price of MXN1,543.00 (31.6% below fair value)
  • GF Score™: 77/100 with 1 warning sign

No single metric tells the full story. See the MEX:ABT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Abbott Laboratories Business Description

Address 100 Abbott Park Road, Abbott Park, IL, USA, 60064-6400
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
77GF Score

Get the complete analysis for MEX:ABT

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1,543.00
Price
MXN2,254.78
GF Value